Swiss psychoanalyst Hermann Rorschach formalized this idea through the inkblot test he created—he noticed that people with schizophrenia tended to perceive the images differently than did other ...

The phase 2 trial represented a key test of that idea ... after five weeks in a phase 3 trial that enrolled 256 people with schizophrenia experiencing acute psychosis. Neurocrine Biosciences ...

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials.

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

My name is Bethany Yeiser. I live a fulfilling life in full recovery from schizophrenia. Through my work as a schizophrenia advocate and nonprofit president, I have found great purpose and meaning.

There are as yet no effective drugs for negative symptoms like social withdrawal and lack of motivation. Read more at ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...